We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blocking Glycolysis Helps Antimitotic Chemotherapeutic Drugs to Work Better

By LabMedica International staff writers
Posted on 15 Sep 2015
Print article
Image: During the process of cell division, the mitochondria are damaged (yellow indicator) making the cells particularly dependent on glucose as a source of energy. Genetic material is shown in blue and mitochondria in red (Photo courtesy of the Spanish National Cancer Research Center).
Image: During the process of cell division, the mitochondria are damaged (yellow indicator) making the cells particularly dependent on glucose as a source of energy. Genetic material is shown in blue and mitochondria in red (Photo courtesy of the Spanish National Cancer Research Center).
Blocking the attempts of tumor cells to establish glycolysis as their primary means of generating energy was found to significantly augment the chemotherapeutic benefits of drugs that prevent the cells from dividing.

Cancer researchers have long wondered how tumor cells survived when their ability to divide was disrupted by treatment with antimitotic drugs such as the toxanes (paclitaxel and docetaxel) or alkaloids derived from Vinca (Catharanthus roseus), such as vinblastine, vincristine, and vinorelbine.

Investigators at the Spanish National Cancer Research Center (Madrid, Spain) were among groups looking into this question. They reported in the August 31, 2015, online edition of the journal Nature Cell Biology that survival during mitotic arrest was affected by the special energetic requirements of mitotic cells. Prolonged mitotic arrest resulted in mitophagy-dependent loss of mitochondria, accompanied by reduced ATP levels and the activation of AMPK (5' adenosine monophosphate-activated protein kinase).

Oxidative respiration in cells undergoing mitotic arrest was replaced by glycolysis owing to AMPK-dependent phosphorylation of PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3) and increased production of this protein as a consequence of mitotic-specific translational activation of its mRNA. Induction of autophagy or inhibition of AMPK or PFKFB3 resulted in enhanced cell death in mitosis and improved the anticancer efficiency of chemotherapeutic agents (microtubule poisons) in breast cancer cells.

"The therapeutic value of inhibiting PFKFB3 has often been discussed; however, no appropriate cell-based scenario had been proposed for its clinical use. Our results suggest that PFKFB3 inhibitors can be extremely efficient in combination with antimitotic drugs," said senior author Dr. Marcos Malumbres, head of the cell division and cancer group at the Spanish National Cancer Research Center.

Related Links:

Spanish National Cancer Research Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.